tiprankstipranks
Trending News
More News >
Exagen Inc (XGN)
NASDAQ:XGN
Advertisement

Exagen (XGN) AI Stock Analysis

Compare
174 Followers

Top Page

XGN

Exagen

(NASDAQ:XGN)

Rating:61Neutral
Price Target:
$10.50
▲(6.82% Upside)
Exagen's stock score is primarily driven by strong technical momentum and a positive earnings call, reflecting growth potential. However, challenges in profitability and valuation weigh down the overall score.
Positive Factors
Operational Strategies
The focus on cutting the cash burn via narrowing the commercial efforts to focus on profitable accounts is paying off.
Revenue and Earnings
XGN delivered a 5% revenue beat in Q2 and grew the top line by 14% driven by balanced growth from volume and pricing gains.
Valuation and Market Performance
Shares of XGN are up a very strong 105% as the company seems to be finally gaining some 'valuation support' for the good operational work it is putting in.
Negative Factors
Debt and Financial Flexibility
Exagen's new credit facility enabled it to refinance its debt and provides additional capital for future needs.
Financial Targets
Management anticipates reaching AEBITDA positivity in the fourth quarter if revenue hits the high end of its revised guidance.
Market Penetration
With <10% market penetration and an expanding sales force, management sounds confident that this volume growth is sustainable.

Exagen (XGN) vs. SPDR S&P 500 ETF (SPY)

Exagen Business Overview & Revenue Model

Company DescriptionExagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
How the Company Makes MoneyExagen generates revenue primarily through the sale of its diagnostic tests to healthcare providers and laboratories. The company operates on a fee-for-service model, where it charges for each test performed. Key revenue streams include direct sales of AVISE® tests to clinicians, reimbursement from insurance companies for tests provided to patients, and collaborations with pharmaceutical companies for companion diagnostics. Additionally, Exagen may benefit from partnerships with healthcare organizations that enhance its market reach and credibility, contributing to its overall earnings potential.

Exagen Earnings Call Summary

Earnings Call Date:Jul 29, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook for Exagen, marked by record revenue growth, successful biomarker launches, and strategic leadership additions. While there are challenges related to operating losses and increased expenses, the company's strong cash position and positive revenue guidance indicate resilience and growth potential.
Q2-2025 Updates
Positive Updates
Record Revenue Achieved
Exagen reported Q2 revenue of $17.2 million, marking a 14% year-over-year growth and the highest quarterly revenue in company history.
Significant Per Territory Revenue Growth
Average revenue per territory reached over $430,000, a 50% increase from two years ago, reflecting strong commercial leverage.
Successful Biomarker Launch
The launch of novel T cell and RA markers has significantly enhanced commercial discussions and clinical adoption.
Expansion of R&D and Leadership
Exagen made two significant hires: Dr. Michael Mahler as Chief Scientific Officer and Chas McKhann to the Board of Directors, enhancing the company's scientific credibility and strategic direction.
Strong Cash Position
The company ended the quarter with over $30 million in cash and equivalents, with a path towards neutral operating cash flow.
Positive Revenue Guidance
Exagen provided a full-year revenue guidance of between $65 million and $70 million, with expectations of positive adjusted EBITDA in Q4.
Negative Updates
Operating Losses
The net loss for the second quarter was $4.4 million, up from $3 million in the same period last year, partly due to new debt facility costs.
Incremental Operating Expense Increases
Operating expenses increased to $13 million from $11.6 million in Q2 2024, reflecting one-time expenses and investments in R&D and commercial expansion.
Noncash Interest and Debt Extinguishment Costs
The new debt facility added $600,000 in noncash interest and fair value adjustments, and $300,000 for loss on debt extinguishment.
Company Guidance
During the Exagen Inc. Q2 2025 earnings call, the company reported record revenue of $17.2 million, marking a 14% year-over-year growth. The AVISE CTD test saw substantial volume growth, with an average revenue per territory of over $430,000, a significant increase from $285,000 per territory a few years prior. The company's strategy focuses on organic growth driven by existing commercial teams and the clinical recognition of its differentiated science. Exagen maintained 40 territories as of Q2, but anticipates further expansion to potentially 45 by year-end. The call highlighted ongoing improvements in revenue cycle efforts and consistent ordering patterns from high-value clinicians. Additionally, the company launched novel biomarkers that have been well-received by clinicians, contributing to increased ASP, which grew by $27 year-over-year to $428. Exagen also ended the quarter with over $30 million in cash and equivalents, positioning itself for a path to profitability, with full-year revenue guidance of $65 million to $70 million.

Exagen Financial Statement Overview

Summary
Exagen shows revenue growth and a strong gross profit margin, but struggles with profitability and cash flow. The balance sheet is stable with low leverage, yet operational inefficiencies hinder shareholder returns.
Income Statement
45
Neutral
Exagen's TTM (Trailing-Twelve-Months) revenue grew by 5.79% compared to the previous annual report, indicating a positive trend. However, the company is struggling with profitability, as evidenced by negative EBIT and net profit margins. The gross profit margin at 59.43% shows that core operations are relatively efficient, but overall profitability is impacted by high operating expenses.
Balance Sheet
55
Neutral
The balance sheet shows a debt-to-equity ratio of 0.14, indicating low leverage, which is a positive sign of financial stability. However, the return on equity is negative due to ongoing net losses, reflecting challenges in generating profits from shareholder investments. The equity ratio of 35.79% shows moderate reliance on equity financing.
Cash Flow
40
Negative
Operating cash flow remains negative, indicating challenges in generating cash from operations. The free cash flow to net income ratio is unfavorable, highlighting cash flow constraints. Despite negative free cash flow growth, the company has managed to secure significant financing, which supports liquidity.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue58.86M55.64M52.55M45.56M48.30M41.98M
Gross Profit34.98M33.11M29.46M21.35M27.71M25.42M
EBITDA-12.21M-11.14M-19.15M-43.11M-23.10M-13.65M
Net Income-16.98M-15.12M-23.69M-47.39M-26.85M-16.69M
Balance Sheet
Total Assets58.76M44.69M56.94M86.22M123.44M78.38M
Cash, Cash Equivalents and Short-Term Investments30.03M22.04M36.49M62.39M99.44M57.45M
Total Debt2.89M23.36M23.72M36.05M28.07M26.97M
Total Liabilities37.73M35.15M34.25M43.76M38.51M36.54M
Stockholders Equity21.03M9.54M22.69M42.46M84.94M41.84M
Cash Flow
Free Cash Flow-15.98M-13.79M-15.29M-36.46M-22.64M-14.54M
Operating Cash Flow-15.37M-13.28M-14.46M-32.14M-20.27M-14.08M
Investing Cash Flow-609.00K-515.00K-804.00K-4.32M-2.42M-455.00K
Financing Cash Flow21.53M-663.00K-10.63M-489.00K64.68M-97.00K

Exagen Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.83
Price Trends
50DMA
8.31
Positive
100DMA
7.31
Positive
200DMA
5.67
Positive
Market Momentum
MACD
0.40
Positive
RSI
62.67
Neutral
STOCH
30.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XGN, the sentiment is Positive. The current price of 9.83 is above the 20-day moving average (MA) of 9.65, above the 50-day MA of 8.31, and above the 200-day MA of 5.67, indicating a bullish trend. The MACD of 0.40 indicates Positive momentum. The RSI at 62.67 is Neutral, neither overbought nor oversold. The STOCH value of 30.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XGN.

Exagen Risk Analysis

Exagen disclosed 71 risk factors in its most recent earnings report. Exagen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Exagen Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$216.30M-87.94%3.89%7.92%
54
Neutral
$174.73M-1552.23%22.56%41.62%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
51
Neutral
$90.93M-37.15%-0.26%60.09%
47
Neutral
$63.58M-219.68%25.70%39.23%
44
Neutral
$126.75M-44.24%0.93%13.99%
43
Neutral
$71.36M138.92%35.10%39.15%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XGN
Exagen
9.83
6.41
187.43%
VNRX
VolitionRX
0.63
-0.09
-12.50%
MDXH
MDxHealth
3.53
0.67
23.43%
BNR
Burning Rock Biotech
8.45
3.75
79.79%
BDSX
Biodesix
0.44
-1.41
-76.22%
SERA
Sera Prognostics
3.41
-3.81
-52.77%

Exagen Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Exagen Appoints Chas McKhann to Board of Directors
Positive
Jul 17, 2025

On July 17, 2025, Exagen Inc. announced the appointment of Chas McKhann to its Board of Directors, highlighting his extensive experience in the life sciences industry and previous leadership roles in companies acquired by Boston Scientific. This strategic move is expected to bolster Exagen’s growth and enhance its position in the autoimmune diagnostics market, aiming to drive strategic growth and create long-term value for patients, providers, and shareholders.

Executive/Board ChangesShareholder Meetings
Exagen Inc. Holds 2025 Annual Stockholder Meeting
Neutral
Jun 11, 2025

Exagen Inc. held its 2025 annual meeting of stockholders on June 10, 2025, where four proposals were voted on. The stockholders elected two Class III directors for a three-year term, ratified the appointment of BDO USA, P.C. as the independent auditor for 2025, approved executive compensation, and decided to hold annual advisory votes on executive compensation.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025